• 1
    Elmer PJ, Brown JB, Nichols GA, Oster G. Effects of weight gain on medical care costs. Int J Obes Relat Metab Disord 2004; 28: 136573.
  • 2
    US Preventive Services Task Force (USPSTF). Screening for obesity in adults. Recommendations and rationale. Ann Intern Med 2003; 139: 9302.
  • 3
    Maggard MA, Shugarman LR, Suttorp M et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142: 54759.
  • 4
    Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294: 190917.
  • 5
    National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. Obes Res 1998; 6 (Suppl. 2) :51S209S.
  • 6
    Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 172437.
  • 7
    Nelson WK, Fatima J, Houghton SG et al. The malabsorptive very, very long limb Roux-en-Y gastric bypass for super obesity: results in 257 patients. Surgery 2006; 140: 51722, , discussion 522-513,
  • 8
    Schauer PR, Kashyap SR, Wolski K et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 156776.
  • 9
    Mingrone G, Panunzi S, De Gaetano A et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 157785.
  • 10
    Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004; 239: 111.
  • 11
    Rubino F, Zizzari P, Tomasetto C et al. The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. Endocrinology 2005; 146: 174551.
  • 12
    Cummings DE, Overduin J, Foster-Schubert KE, Carlson MJ. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis 2007; 3: 10915.
  • 13
    Mumphrey M, Patterson L, Zheng H, Berthoud HR. Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1, 5-HT- and neurotensin-expressing enteroendocrine cells in rats. Neurogastroenterol Motil, 2013 (in press).
  • 14
    Smushkin G, Sathananthan A, Dalla Man C et al. Defects in GLP-1 response to an oral challenge do not play a significant role in the pathogenesis of prediabetes. J Clin Endocrinol Metab 2012; 97: 58998.
  • 15
    Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003; 52: 114754.
  • 16
    Reimann F, Gribble FM. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002; 51: 275763.
  • 17
    Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 128793.
  • 18
    Wadden TA, Foster GD, Letizia KA, Stunkard AJ. A multicenter evaluation of a proprietary weight reduction program for the treatment of marked obesity. Arch Intern Med 1992; 152: 9616.
  • 19
    Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 2005; 15: 47481.
  • 20
    Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 2004; 36: 8306.